Translational Research in Cancer Immunotherapy and Epigenetics
Lines of Research
01.Oncology and Hematology
02.Cancer Immunotherapy
- Research projects
- Clinical studies
- Scientific Publications
- Technological Offers
- Industrial property records
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Ensayo de fase II abierto, aleatorizado, de BNT113 en combinación con pembrolizumab frente a pembrolizumab en monoterapia como tratamiento de primera línea para pacientes con carcinoma de células escamosas de cabeza y cuello (CCECC) irresecable, recurrente o metastásico, que es positivo para el genotipo 16 del virus del papiloma humano (VPH16+) y expresa PD-L1
ANTONIO RUEDA DOMÍNGUEZ – ENSAYO CLINICO COMERCIAL – II – SYNEOS HEALTH UK LIMITED
Ensayo de Fase 3, Abierto, Aleatorizado y Multicéntrico para Evaluar la Eficacia y Seguridad de Trastuzumab Deruxtecan como Tratamiento de Primera Línea en Cáncer de Pulmón No Microcítico, no Resecable y localmente Avanzado o Metastásico que presenta mutación del Exon 19 o 20 de HER2 (Destiny-Lung04)
ALEJANDRA CANTERO GONZÁLEZ – ENSAYO CLINICO COMERCIAL – III – ASTRAZENECA FARMACEUTICA ESPAÑA S.A.
Ensayo clínico de fase II de un solo brazo para evaluar la eficacia y seguridad de Bintrafusp alfa (M7824) en el mesotelioma pleural maligno avanzado previamente tratado (BIMES).
JOSE CARLOS BENÍTEZ MONTAÑÉS – ENSAYO CLINICO INDEPENDIENTE – II – FUNDACIÓN GECP
Ensayo aleatorizado fase III de nivolumab en adyuvancia y quimioterapia concomitante en pacientes de alto riesgo con carcinoma de células escamosas de cabeza y cuello resecado (NIVO POST-OP)
ANTONIO RUEDA DOMÍNGUEZ – ENSAYO CLINICO INDEPENDIENTE – III – GORTEC (GROUPE D’ONCOLOGIE READIOTHÉRAPIE TÊTE ET COU)
DAREON™-5: Estudio abierto, multicéntrica fase II de selección de dosis intravenosa de BI 764532, un T cell engager dirigido a DLL3, en pacientes con cáncer extensivo de pulmón microcítico refractario o en recaída y en pacientes con otras carcinomas neuroendocrinos refractarios o en recaída.
JOSE CARLOS BENÍTEZ MONTAÑÉS – ENSAYO CLINICO CON MEDICAMENTOS – II – BOEHRINGER INGELHEIM ESPAÑA, S.A.
BelieveIT-201: A Randomized, Phase 2, Open-label Trial of TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 ß/?, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
ANTONIO RUEDA DOMÍNGUEZ – ENSAYO CLINICO CON MEDICAMENTOS – II – ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S
An observational study to assess the effectiveness and safety of cemiplimab in patients with advanced non-small cell lung cancer (NSCLC) in routine clinical practice settings in Europe (CEMI-LUNG).
JOSE CARLOS BENÍTEZ MONTAÑÉS – ESTUDIO OBSERVACIONAL CON MEDICAMENTOS – No aplica – REGENERON PHARMACEUTICALS, INC
A Randomized Study of Two Dosing Regimens of Adagrasib in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
ALEJANDRA CANTERO GONZÁLEZ – ENSAYO CLINICO CON MEDICAMENTOS – II – PAREXEL INTERNATIONAL (IRL) LIMITED
A randomised, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after secondary resistance to anti-PD(L)1 inhibitors.
ALEJANDRA CANTERO GONZÁLEZ – ENSAYO CLINICO CON MEDICAMENTOS – III – ICON CLINICAL RESEARCH LTD
A phase 3 randomized, controlled study of IMC-F106C plus Nivolumab versus Nivolumab regimens in HLA-A202:01-positive participants with previously untreated advanced melanoma (PRISM-MEL-301)
ELISABETH PEREZ RUIZ – ENSAYO CLINICO CON MEDICAMENTOS – III – IMMUNOCORE LIMITED
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor
JOSE CARLOS BENÍTEZ MONTAÑÉS – ENSAYO CLINICO COMERCIAL – II – GENMAB A/S
A Phase 1 Study of ASP3082 in Participants with Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies with KRAS G12D Mutation
JOSE CARLOS BENÍTEZ MONTAÑÉS – ENSAYO CLINICO CON MEDICAMENTOS – I – ASTELLAS PHARMA GLOBAL DEVELOPMENT INC.
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic factors in locally advanced rectal cancer – ONCOLOGY
Duque-Santana, V; López-Campos, F; Martin-Martin, M; Valero, M; Zafra-Martín, J; Couñago, F; Sancho, S – 2023 – 10.1159/000526450
Novel Approaches in the Systemic Management of High-Risk Prostate Cancer – CLINICAL GENITOURINARY CANCER
Gómez-Aparicio, MA; López-Campos, F; Lozano, AJ; Maldonado, X; Caballero, B; Zafra, J; Suarez, V; Moreno, E; Arcangeli, S; Scorsetti, M; Couñago, F – 2023 – 10.1016/j.clgc.2023.06.001
Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy? – CLINICAL GENITOURINARY CANCER
Los Arcos, Marta Barrado; Lopez-Campos, Fernando; Valcarcel, Marta Lopez; Rubio, Manuel Galdeano; de Manzanos, Ignacio Visus Fernandez; Duque-Santana, Victor; Aparicio, Marian Gomez; Martin, Juan Zafra; Kishan, Amar U.; Achard, Verane; Siva, Shankar; Counago, Felipe – 2023 – 10.1016/j.clgc.2022.10.015
Preclinical models in head and neck squamous cell carcinoma – BRITISH JOURNAL OF CANCER
Chaves, P; Garrido, M; Oliver, J; Perez-Ruiz, E; Barragan, I; Rueda-Dominguez, A – 2023 – 10.1038/s41416-023-02186-1
Abnormal cannabidiol ameliorates inflammation preserving pancreatic beta cells in mouse models of experimental type 1 diabetes and beta cell damage
Gonzalez-Mariscal, I; Pozo-Morales, M; Romero-Zerbo, SY; Espinosa-Jimenez, V; Escamilla-Sanchez, A; Sanchez-Salido, L; Cobo-Vuilleumier, N; Gauthier, BR; Bermudez-Silva, FJ – 2022
Defining a Standard Set of Health Outcomes for Patients With Squamous Cell Carcinoma of the Head and Neck in Spain
Arrazubi, V; Cajaraville, G; Cantero, D; Giralt, J; Mesia, R; Monje, F; Rueda, A; Sistiaga, A; Suarez, J; Mut, A; Comellas, M; Lizan, L – 2022
SEOM-TTCC clinical guideline in nasopharynx cancer (2021)
Dominguez, AR; Cirauqui, B; Castano, AG; Cabellos, RA; Maseda, AC; Fernandez, BC; Rey, LI; Rubio-Casadevall, J; Arrazubi, V; Mesia, R – 2022
Acceleration of the DNA methylation clock among lynch syndrome-associated mutation carriers
Cuadros, M; Cano, C; Garcia-Rodriguez, S; Martin, JL; Poyatos-Andujar, A; Ruiz-Cabello, F; Pedrinaci, S; Duran, G; Benavides, M; Bautista-Ojeda, MD; Pereda, T; Benitez-Cantos, MS; Medina, P; Blanco, A; Gonzalez, A; Lizardi, P – 2022
Development of a mouse model for spontaneous oral squamous cell carcinoma in Fanconi anemia.
Errazquin, Ricardo; Page, Angustias; Sunol, Anna; Segrelles, Carmen; Carrasco, Estela; Peral, Jorge; Garrido-Aranda, Alicia; Del Marro, Sonia; Ortiz, Jessica; Lorz, Corina; Minguillon, Jordi; Surralles, Jordi; Belendez, Cristina; Alvarez, Martina; Balmana, Judith; Bravo, Ana; Ramirez, Angel; Garcia-Escudero, Ramon – 2022
Treatment of Metastatic Melanoma at First Diagnosis: Review of the Literature
Berciano-Guerrero, MA; Guardamagna, M; Perez-Ruiz, E; Jurado, JM; Barragan, I; Rueda-Dominguez, A – 2022
Emerging noninvasive methylation biomarkers of cancer prognosis and drug response prediction.
Oliver, J; Garcia-Aranda, M; Chaves, P; Alba, E; Cobo-Dols, M; Onieva, JL; Barrgan, I – 2022
Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine-refractory differentiated thyroid cancer
Berciano-Guerrero, MA – 2022
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.
Pascual, J; Attard, G; Bidard, F-C; Curigliano, G; De Mattos-Arruda, L; Diehn, M; Italiano, A; Lindberg, J; Merker, J D; Montagut, C; Normanno, N; Pantel, K; Pentheroudakis, G; Popat, S; Reis-Filho, J S; Tie, J; Seoane, J; Tarazona, N; Yoshino, T; Turner, N C – 2022
Association of Circular RNA and Long Non-Coding RNA Dysregulation with the Clinical Response to Immune Checkpoint Blockade in Cutaneous Metastatic Melanoma
Oliver, J; Onieva, JL; Garrido-Barros, M; Berciano-Guerrero, MA; Sanchez-Munoz, A; Lozano, MJ; Farngren, A; Alvarez, M; Martinez-Galvez, B; Perez-Ruiz, E; Alba, E; Cobo, M; Rueda-Dominguez, A; Barragan, I – 2022
Genes Involved in Immune Reinduction May Constitute Biomarkers of Response for Metastatic Melanoma Patients Treated with Targeted Therapy,
Berciano-Guerrero, MA; Lavado-Valenzuela, R; Moya, A; delaCruz-Merino, L; Toscano, F; Valdivia, J; Castellon, V; Henao-Carrasco, F; Sancho, P; Onieva-Zafra, JL; Navas-Delgado, I; Rueda-Dominguez, A; Perez-Ruiz, E; Alba, E – 2022
Bone health and therapeutic agents in advanced prostate cancer
Gomez-Aparicio, MA; Lopez-Campos, F; Pelari-Mici, L; Buchser, D; Pastor, J; Maldonado, X; Zafra, J; Tree, AC; Bultijnck, R; Sargos, P; Ost, P; Counago, F – 2022
Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition
Guardamagna, M; Berciano-Guerrero, MA; Villaescusa-Gonzalez, B; Perez-Ruiz, E; Oliver, J; Lavado-Valenzuela, R; Rueda-Dominguez, A; Barragan, I; Queipo-Ortuno, MI – 2022
High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade;
Onieva, JL; Xiao, QY; Berciano-Guerrero, MA; Laborda-Illanes, A; de Andrea, C; Chaves, P; Pineiro, P; Garrido-Aranda, A; Gallego, E; Sojo, B; Galvez, L; Chica-Parrado, R; Prieto, D; Perez-Ruiz, E; Farngren, A; Lozano, MJ; Alvarez, M; Jimenez, P; Sanchez-Munoz, A; Oliver, J; Cobo, M; Alba, E; Barragan, I – 2022
IJRadiation therapy for recurrent hydatid cyst of the pelvic bone: a case report
Huertas, MP; Martin, JZ; de Quesada, IAG; Gavela, AAD; Gomez, LLG; Garcia, SS; Perez, EP; Counago, F; Penalver, ED – 2022
Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions
Lopez-Campos, F; Gajate, P; Romero-Laorden, N; Zafra-Martin, J; Juan, M; Polo, SH; Moreno, AC; Counago, F – 2022
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Members
-
Researcher in ChargeSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.

Antonio Rueda Domínguez
-
Co-Investigadora ResponsableSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.

María Isabel Barragán Mallofret
-
Investigador/a SéniorSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Investigador/a Asistencial Colaborador/aSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Investigadores/as posdoctorales y/o juniorSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Investigadores/as predoctorales y/o en formaciónSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Technical staffSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.